Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Shenzhen Investor Forms $23 Million China JV with Montreal's Prometic

publication date: Mar 31, 2017
Shenzhen Royal Asset Management (SRAM) set up a joint venture with Prometic Life Sciences (TO: PLL), a Montreal area biopharma, to develop three clinical-stage Prometic molecules in China. Prometic will contribute the three candidates to the JV, known as Prometic ChinaCo. The molecules target kidney disease, lung and liver fibrosis. SRAM will invest $23 million in 2017 ($13 million upfront) and for an initial 17% stake in the JV. It has an option to add another $10 million to bring its share of the JV up to 25% following milestones expected in 2018. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital